source
- Relay Therapeutics' zovegalisib meets efficacy endpoint in Phase 2 vascular anomalies trialRelay Therapeutics reported that its PI3Kα inhibitor zovegalisib achieved the predefined efficacy threshold in a Phase 2 study of a rare genetic vascular anomaly. The data readout exceeded Wall Str…
- BioMarin's Phase 3 trial of ENPP1 enzyme therapy fails to show benefitBioMarin reported that its late-stage study of an enzyme replacement therapy for ENPP1 deficiency did not meet its primary efficacy endpoints. The trial, which enrolled patients lacking the ENPP1 e…